Harpaz N, Peck A L, Yin J, Fiel I, Hontanosas M, Tong T R, Laurin J N, Abraham J M, Greenwald B D, Meltzer S J
Department of Pathology, Mount Sinai Medical School, City University of New York, NY 10029.
Hum Pathol. 1994 Oct;25(10):1069-74. doi: 10.1016/0046-8177(94)90067-1.
The frequency and timing of p53 inactivation in ulcerative colitis (UC)-associated tumorigenesis were investigated using immunohistochemistry (IHC) to detect p53 protein overexpression in 56 carcinomas and 40 dysplastic epithelia derived from 58 patients with UC undergoing colectomy for neoplasia. p53 DNA in 25 of the carcinomas also was evaluated by single-strand conformation polymorphism analysis (SSCP) to detect point mutations in exons 5-8 and by loss of heterozygosity analysis to detect allelic deletions. Point mutations were detected in 20 of the 25 carcinomas (80.0%) undergoing both IHC and DNA analysis. One carcinoma contained an allelic deletion but no mutations of the corresponding allele within the region tested. p53 overexpression occurred in 16 (76.2%) of the 21 carcinomas with point mutations and/or allelic deletions but not in any of those with wild type DNA. Of the 56 carcinomas evaluated by IHC, p53 overexpression occurred in 34 carcinomas (60.7%). The proportion of positive tumors was independent of stage, anatomic location, differentiation, and histological subtype. Overexpression was observed in nine of 20 dysplastic masses devoid of and situated remote from carcinoma (45.0%) and correlated positively with increasing grade of dysplasia (P < .025). In contrast, overexpression occurred in 16 of 20 dysplastic epithelia situated adjacent to carcinoma (80.0%) and correlated with overexpression by the corresponding carcinomas but not with the grade of dysplasia present (P = .013). It is concluded that p53 overexpression can be detected by IHC in most, although not all, UC-associated carcinomas with p53 mutations and/or allelic deletions. Based on this method, p53 overexpression occurs frequently in UC-associated carcinomas regardless of stage and pathological characteristics, in noncancerous dysplastic masses with high grade dysplasia, and in dysplasias of all grades situated adjacent to carcinomas. These findings implicate p53 inactivation in the progression from dysplasia to carcinoma in UC and suggest that its occurrence in dysplastic epithelium may be an independent marker of malignant potential.
采用免疫组织化学(IHC)方法,对58例因肿瘤而行结肠切除术的溃疡性结肠炎(UC)患者的56例癌组织和40例发育异常上皮组织中p53蛋白过表达情况进行检测,以研究UC相关肿瘤发生过程中p53失活的频率和时间。对其中25例癌组织的p53 DNA也通过单链构象多态性分析(SSCP)检测外显子5 - 8中的点突变,并通过杂合性缺失分析检测等位基因缺失。在接受IHC和DNA分析的25例癌组织中,有20例(80.0%)检测到点突变。1例癌组织存在等位基因缺失,但在检测区域内相应等位基因无突变。在21例有 点突变和/或等位基因缺失的癌组织中,16例(76.2%)出现p53过表达,而野生型DNA的癌组织均未出现p53过表达。在通过IHC评估的56例癌组织中,34例(60.7%)出现p53过表达。阳性肿瘤比例与分期、解剖位置、分化程度及组织学亚型无关。在20例无癌且远离癌的发育异常肿块中,9例(45.0%)出现过表达,且与发育异常程度增加呈正相关(P < 0.025)。相比之下,在20例紧邻癌的发育异常上皮组织中,16例(80.0%)出现过表达,与相应癌组织的过表达相关,但与存在的发育异常程度无关(P = 0.013)。得出结论:通过IHC可在大多数(虽非全部)有p53突变和/或等位基因缺失的UC相关癌组织中检测到p53过表达。基于此方法,p53过表达在UC相关癌组织中频繁出现,与分期和病理特征无关,在高级别发育异常的非癌性发育异常肿块中以及紧邻癌的各级发育异常中均有出现。这些发现提示p53失活参与了UC中从发育异常到癌的进展过程,并表明其在发育异常上皮中的出现可能是恶性潜能的独立标志物。